Cengild Medical Bhd’s has partnered with Curie KL Sdn Bhd and OnCocare Holdings Sdn Bhd to establish oncology centres in the Klang Valley.
In a filing with Bursa Malaysia, the wholly-owned subsidiary Cengild Sdn Bhd will hold a 25% stake in the joint venture company, Curie Oncology KL Sdn Bhd, while Curie KL will own a majority 65% stake and OnCoCare, the remaining 10%.
The joint venture company will establish its first oncology centre and carry out its operations at Cengild GI Medical Centre at Nexus@Bangsar South.
“The joint venture represents an opportunity for Cengild Medical to partner with Curie Oncology group of companies (through Curie KL) and to leverage Curie Oncology’s core competencies in complex oncology given its early adoption of technology in medical diagnostics and treatment for cancer.
“The joint venture enables Cengild Medical to broaden its capability in providing complex oncology services, which are complementary to its core specialisation in gastrointestinal and liver diseases, and obesity,” said Cengild.
